Company news

Arcturus Therapeutics Holdings Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference

March 13, 2022

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress

February 27, 2022

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

February 15, 2022

Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

February 7, 2022

Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial

January 24, 2022

Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants

January 23, 2022

Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials

December 15, 2021

Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors

December 12, 2021

Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

November 21, 2021

Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress

November 7, 2021

Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021

October 24, 2021

Arcturus Therapeutics Announces Leadership Appointments

October 20, 2021

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

October 11, 2021

Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration

September 21, 2021

Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern

September 21, 2021

Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021

September 7, 2021

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

September 6, 2021

Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress

August 8, 2021

Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study

August 2, 2021

Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19

August 1, 2021

Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern

August 1, 2021

Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

July 27, 2021

Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021

July 25, 2021

Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data

May 9, 2021

Arcturus Therapeutics to Report First Quarter 2021 Financial Results and Provide Corporate Update on May 10, 2021

May 2, 2021

Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates

February 28, 2021

Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals

February 21, 2021

Arcturus Therapeutics to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Corporate Update on March 1, 2021

February 18, 2021

Arcturus Therapeutics to Present at Upcoming Investor Conferences

February 10, 2021

Arcturus Therapeutics to Present at Upcoming Investor Conference

January 5, 2021

Arcturus Therapeutics Receives FDA Allowance to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate in the United States

January 3, 2021

Arcturus Therapeutics to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Therapeutic, as a Development Candidate for Cystic Fibrosis Lung Disease

December 29, 2020

Arcturus Therapeutics Received Approval from Singapore Health Sciences Authority to Proceed with Phase 2 Study of ARCT-021 (LUNAR-COV19) Vaccine Candidate and Provides New and Updated Clinical and Preclinical Data

December 27, 2020

Arcturus Therapeutics Announces Proposed Public Offering of Common Stock

December 6, 2020

Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

December 6, 2020

Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency

December 6, 2020

Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data

November 8, 2020

Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore

November 8, 2020

Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020

October 29, 2020

Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency

October 4, 2020

Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference

September 30, 2020

Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate

September 3, 2020

Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health

August 17, 2020

Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study

August 10, 2020

Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update

August 9, 2020

Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer

August 5, 2020

Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020

August 3, 2020

Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

July 30, 2020

Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock

July 28, 2020

Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19

July 22, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 25 calls. Every call is listed under its year.

Decks

The 5 newest of 22 decks. Every deck is listed under its year.